Health Care & Life Sciences » Biotechnology | Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
12 M
Public Float
9.66 M
Cyclacel Pharmaceuticals Inc. 6% Conv. Pfd.
Stock Exchange NASDAQ Stock Market
EPS
-
Market Cap
-
Shares Outstanding
335 K
Public Float
333.67 K
Cyclacel Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.65
Market Cap
$10.01 M
Shares Outstanding
17.2 M
Public Float
12.34 M

Profile

Address
200 Connell Drive
Berkeley Heights New Jersey 07922
United States
Employees -
Website http://www.cyclacel.com
Updated 07/08/2019
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

Financials

View All
Created with Highcharts 5.0.14Cyclacel Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.10 21010 21019 40619 40614 34214 34211 79111 7917 4707 4707 2887 28820132014201520162017201805k10k15k20k25k
Created with Highcharts 5.0.14Cyclacel Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.1 0841 0841 7341 7341 9441 9448438430015015020132014201520162017201805001000150020002500

Spiro Rombotis
President, Chief Executive Officer & Director
Paul McBarron
COO, CFO, Secretary, Director & Executive VP